Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?

Basit Öğe Kaydı
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorBas, Volkan
dc.contributor.authorUmit, Elif
dc.contributor.authorKirkizlar, Hakki Onur
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2024-06-12T10:52:03Z
dc.date.available2024-06-12T10:52:03Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despite being widely used, more markers to predict the response to eltrombopag are still needed. In the present study, we aimed to show the association between ANA positivity and eltrombopag response in ITP patients. Materials and Methods: Patients who were diagnosed with ITP in the Trakya University Faculty of Medicine's Department of Hematology and who underwent eltrombopag treatment due to their resistance to steroids and other treatments were included in our study. ANA measurement was performed by indirect fluorescent antibody method and titers of 1:160 and above were considered positive. ANA measurements were made before starting eltrombopag. Results: Forty-five patients were included in our study, 33 being women and 12 men. The mean age of the patients was 45.73 years. There were 14 patients with ANA positivity and 31 patients were found to be ANA-negative. Response rates were higher in ANA-negative patients compared to ANA-positive patients in the 1st and 6th months of eltrombopag treatment (p<0.05). Conclusion: ANA positivity in ITP may indicate unresponsiveness to eltrombopag treatment, a finding that should be further supported by prospective studies involving more patients.en_US
dc.identifier.doi10.4274/tjh.galenos.2021.2021.0183
dc.identifier.endpage42en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue1en_US
dc.identifier.pmid34162172en_US
dc.identifier.scopus2-s2.0-85125212089en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage38en_US
dc.identifier.trdizinid522014en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2021.2021.0183
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/522014
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18580
dc.identifier.volume39en_US
dc.identifier.wosWOS:000761303000005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAntinuclear Antibodiesen_US
dc.subjectEltrombopagen_US
dc.subjectImmune Thrombocytopeniaen_US
dc.subjectClinical-Significanceen_US
dc.subjectAdult Patientsen_US
dc.subjectPrevalenceen_US
dc.subjectChildrenen_US
dc.titleCould Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu